MDinteractive is an approved CMS Qualified Registry for 2021.

APM Performance Pathway Webinar May 20 at 1 p.m. Register.

MDinteractive accepting customers for Cohort 2 Primary Care First Applications, due to CMS May 21, 2021

2019 MIPS Measure #462: Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy

Quality ID 462
eMeasure ID CMS645v2
High Priority Measure No
Specifications EHR
Measure Type Process
Specialty Oncology Urology

Measure description

Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater (indicated by HCPCS code) and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.

Register with MDinteractive